This has been a busy year for investment trust launches. James Carthew looks at some of the new offerings that haven't received the fanfare afforded to Woodford Patient Capital.
The Greek debt crisis is urgent but containable, we're told. But if risk is back 'on' after this weekend, perhaps investors have bigger worries?
Too many UK equity income funds have faith in GlaxoSmithKline's ability to maintain its dividend, says a healthcare investor.
The sell-off in the bond markets has focused my mind on how much debt some of my stocks are carrying. It's time for one of them to go.
Litigation finance fund tumbles after a negative US Supreme Court ruling. But are the shares as cheap as they appear?
After a series of changes in recent year the real estate investment trust looks to be back on track, says James Carthew.
Experienced private investor David Kempton is struggling to find anything to buy in difficult markets, apart from UK house builders.
The pioneering emerging markets investment trust has underperformed its index for the past five years. Has it passed its sell-by date?
I can't 'buy on the dips' because I'm fully invested, and switching from 'defensives' into 'cyclicals' doesn't make sense. What can I do?
Our weekly roundup shows Tim Russell's Sanditon trust looking reasonable value for the first time since its launch a year ago.
You've helped me to find lots of useful information on my investments in a part of the Hargreaves Lansdown website I never knew existed. Thanks!
Investors continue to flock to low-charging exchange-traded funds, but their performance can't match that of most investment trusts.
HICL Infrastructure looks cheaper than it has done all year after a drop in the high yielding fund's premium.
Pension funds and insurers are starting to shun coal - as much for investment reasons as moral ones.